Clene reports third quarter 2025 financial results and updates on ALS and MS programs

Reuters11-13

Clene reports third quarter 2025 financial results and updates on ALS and MS programs

Clene Inc. reported cash and cash equivalents of $7.9 million as of September 30, 2025, down from $12.2 million at the end of 2024. Including $1.2 million raised after the third quarter, the company expects its cash runway to extend into the second quarter of 2026. General and administrative expenses were $2.2 million for the third quarter of 2025, a decrease from $3.4 million in the same period of 2024. Total other expense increased to $3.1 million from $0.2 million year-over-year, primarily due to losses from changes in fair value of common stock warrant liabilities and derivative liabilities. Clene reported a net loss of $8.8 million, or $0.85 per share, for the quarter, compared to a net loss of $8.0 million, or $1.22 per share, in the third quarter of 2024. The company plans to submit a New Drug Application for CNM-Au8 in the first quarter of 2026 under an accelerated approval pathway and expects to begin dosing patients in the confirmatory Phase 3 RESTORE-ALS trial in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574749-en) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583560272?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583560272","market":"fut","top_or_hot":-1,"title":"Clene reports third quarter 2025 financial results and updates on ALS and MS programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clene reports third quarter 2025 financial results and updates on ALS and MS programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLNN\">Clene Inc</a>. reported cash and cash equivalents of $7.9 million as of September 30, 2025, down from $12.2 million at the end of 2024. Including $1.2 million raised after the third quarter, the company expects its cash runway to extend into the second quarter of 2026. General and administrative expenses were $2.2 million for the third quarter of 2025, a decrease from $3.4 million in the same period of 2024. Total other expense increased to $3.1 million from $0.2 million year-over-year, primarily due to losses from changes in fair value of common stock warrant liabilities and derivative liabilities. Clene reported a net loss of $8.8 million, or $0.85 per share, for the quarter, compared to a net loss of $8.0 million, or $1.22 per share, in the third quarter of 2024. The company plans to submit a New Drug Application for CNM-Au8 in the first quarter of 2026 under an accelerated approval pathway and expects to begin dosing patients in the confirmatory Phase 3 <a href=\"https://laohu8.com/S/RST.UK\">RESTORE</a>-ALS trial in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574749-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clene reports third quarter 2025 financial results and updates on ALS and MS programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClene reports third quarter 2025 financial results and updates on ALS and MS programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clene reports third quarter 2025 financial results and updates on ALS and MS programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLNN\">Clene Inc</a>. reported cash and cash equivalents of $7.9 million as of September 30, 2025, down from $12.2 million at the end of 2024. Including $1.2 million raised after the third quarter, the company expects its cash runway to extend into the second quarter of 2026. General and administrative expenses were $2.2 million for the third quarter of 2025, a decrease from $3.4 million in the same period of 2024. Total other expense increased to $3.1 million from $0.2 million year-over-year, primarily due to losses from changes in fair value of common stock warrant liabilities and derivative liabilities. Clene reported a net loss of $8.8 million, or $0.85 per share, for the quarter, compared to a net loss of $8.0 million, or $1.22 per share, in the third quarter of 2024. The company plans to submit a New Drug Application for CNM-Au8 in the first quarter of 2026 under an accelerated approval pathway and expects to begin dosing patients in the confirmatory Phase 3 <a href=\"https://laohu8.com/S/RST.UK\">RESTORE</a>-ALS trial in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574749-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL80RwgR:1","article_id":"2583560272","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583560272","pubTimestamp":1763038837,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clene Inc. reported cash and cash equivalents of $7.9 million as of September 30, 2025, down from $12.2 million at the end of 2024. Including $1.2 million raised after the third quarter, the company expects its cash runway to extend into the second quarter of 2026. General and administrative expenses were $2.2 million for the third quarter of 2025, a decrease from $3.4 million in the same period of 2024. Total other expense increased to $3.1 million from $0.2 million year-over-year, primarily due to losses from changes in fair value of common stock warrant liabilities and derivative liabilities. Clene reported a net loss of $8.8 million, or $0.85 per share, for the quarter, compared to a net loss of $8.0 million, or $1.22 per share, in the third quarter of 2024. The company plans to submit a New Drug Application for CNM-Au8 in the first quarter of 2026 under an accelerated approval pathway and expects to begin dosing patients in the confirmatory Phase 3 RESTORE-ALS trial in the first h","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","CLNN":"Clene Inc","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Clene报告2025年第三季度财务业绩以及ALS和MS项目的最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLNN":0.9,"NDAQ":0.9},"content_text":"Clene reports third quarter 2025 financial results and updates on ALS and MS programs\n    \n\nClene Inc. reported cash and cash equivalents of $7.9 million as of September 30, 2025, down from $12.2 million at the end of 2024. Including $1.2 million raised after the third quarter, the company expects its cash runway to extend into the second quarter of 2026. General and administrative expenses were $2.2 million for the third quarter of 2025, a decrease from $3.4 million in the same period of 2024. Total other expense increased to $3.1 million from $0.2 million year-over-year, primarily due to losses from changes in fair value of common stock warrant liabilities and derivative liabilities. Clene reported a net loss of $8.8 million, or $0.85 per share, for the quarter, compared to a net loss of $8.0 million, or $1.22 per share, in the third quarter of 2024. The company plans to submit a New Drug Application for CNM-Au8 in the first quarter of 2026 under an accelerated approval pathway and expects to begin dosing patients in the confirmatory Phase 3 RESTORE-ALS trial in the first half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574749-en) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583560272","isCrawlerRequest":true}